What antidepressant should be prescribed for a generally healthy premenopausal woman requiring treatment, considering efficacy, safety, and side effects?

Antidepressant Selection for Premenopausal Women

For a generally healthy premenopausal woman requiring antidepressant treatment, select a second-generation antidepressant (SSRI or SNRI) based on side effect profile rather than efficacy, as all second-generation antidepressants demonstrate equivalent effectiveness. 1

Primary Recommendation

The American College of Physicians guideline establishes that no second-generation antidepressant demonstrates superior efficacy over another for treating major depression, including in subgroups based on age or sex 1. Therefore, your selection should prioritize:

1. Adverse effect profiles
2. Cost considerations
3. Patient preferences

Side Effect Considerations Critical for Premenopausal Women

Sexual Dysfunction (Key Differentiator)

• Bupropion has significantly lower rates of sexual dysfunction compared to SSRIs and should be strongly considered if sexual side effects are a concern 1
• Paroxetine has the highest rates of sexual dysfunction among SSRIs (higher than fluoxetine, fluvoxamine, nefazodone, or sertraline) 1
• This is particularly relevant for premenopausal women where sexual function impacts quality of life

Common Side Effects Across SSRIs

All second-generation antidepressants share similar rates of 1:

• Nausea and vomiting (most common reason for discontinuation)
• Constipation or diarrhea
• Dizziness and headache
• Insomnia or somnolence

Safety Monitoring Protocol

Begin monitoring within 1-2 weeks of initiation 1. This is critical because:

• SSRIs carry an increased risk for nonfatal suicide attempts compared to placebo 1
• The risk for suicide attempts is greatest during the first 1-2 months of treatment 1
• Monitor specifically for agitation, irritability, or unusual behavioral changes indicating worsening depression 1

Treatment Response Timeline

Modify treatment if inadequate response after 6-8 weeks of therapy 1. This represents a strong recommendation based on moderate-quality evidence and prevents prolonged exposure to ineffective treatment.

Practical Algorithm

Step 1: Discuss sexual side effects with patient

• If sexual function is a priority → Choose bupropion
• If sexual function less concerning → Proceed to Step 2

Step 2: Consider other side effect sensitivities

• Avoid paroxetine (highest sexual dysfunction rates)
• Consider sertraline, fluoxetine, or escitalopram as reasonable alternatives

Step 3: Initiate treatment with close monitoring

• Week 1-2: First assessment for suicidality and emerging symptoms
• Week 6-8: Assess therapeutic response; modify if inadequate

Important Caveats

The guideline evidence does not support pharmacogenetic testing (CYP2D6/CYP2C19) as routine practice for initial antidepressant selection 2. Reserve genetic testing for treatment-resistant cases or when multiple medication failures have occurred.

While combination therapies (antidepressants plus psychotherapy) show enhanced efficacy in some contexts 3, the primary question addresses pharmacotherapy selection. Psychotherapy should be discussed as an adjunct or alternative, but the medication choice itself follows the algorithm above.

The evidence is clear and consistent: efficacy does not differ among second-generation antidepressants 1, 4, making side effect profile the decisive factor for this population.